# Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/PHVS/pharvaris-to-present-clinical-data-at-the-aaaai-2026-annual-meeting-2bd74dbf
Ticker: PHVS
Company: Pharvaris
Source: Pharvaris
Published: 2026-02-10 11:50 EST
## Summary

Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time...

## Article Body
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for poster presentation, three of which will be presented during the Featured Poster session, at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting , to be held from February 27-March 2, 2026, in Philadelphia, PA.

“ Following the announcement of topline RAPIDe-3 data in December of last year, the AAAAI Annual Meeting provides Pharvaris with the first opportunity to share the positive study results with the broader medical community at a large scientific congress, ” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. “ We will also be presenting final data from the open-label portion of CHAPTER-1, the Phase 2 study of deucrictibant for prophylaxis of HAE attacks, and pharmacokinetic data of deucrictibant extended-release tablet, which is being used in the pivotal Phase 3 study of deucrictibant for long-term prophylaxis of HAE attacks, CHAPTER-3. Final efficacy and safety results from approximately three years of deucrictibant treatment from CHAPTER-1 and the data providing further evidence of an optimized extended-release formulation provide strong foundations in advance of the results of CHAPTER-3, topline data from which is anticipated in the third quarter of this year. Additionally, we will be presenting on-demand endpoint validation findings, as well as results from our novel kinin biomarker assay. ”

Details of the presentations are as follows:

Title: A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema Presenter: Evangelia Pardali, Ph.D. Poster Number: 078 Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST

Title: Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks Presenter: Teresa Caballero, M.D., Ph.D. Poster Number: 154 Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST

Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study Presenter: Michael E. Manning, M.D. Poster Number: 159 Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST

Title: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study Presenter: Marc A. Riedl, M.D., M.S. Featured Poster Number: 831 Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST

Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study Presenter: John Anderson, M.D. Featured Poster Number: 832 Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST

Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks Presenter: Zhi-Yi Zhang, Ph.D. Featured Poster Number: 834 Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST

The abstracts are available to view in an online supplement to The Journal of Allergy and Clinical Immunology (JACI) at jacionline.org .

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations .

About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing global marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/ .
## Recent Company News
- 2026-07-22 10:50 EST — [Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema](https://biopharmsignal.com/news/PHVS/publication-in-clinical-reviews-in-allergy-immunology-summarizes-decades-of-evid-a202e0d7) — Source: Pharvaris
- 2026-07-06 10:50 EST — [Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks](https://biopharmsignal.com/news/PHVS/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir--11e9782b) — Source: Pharvaris
- 2026-06-15 10:50 EST — [Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026](https://biopharmsignal.com/news/PHVS/data-supporting-differentiated-profile-of-deucrictibant-in-hae-management-presen-1a36672e) — Source: Pharvaris
- 2026-06-11 10:50 EST — [Pharvaris Announces Annual General Meeting of Shareholders](https://biopharmsignal.com/news/PHVS/pharvaris-announces-annual-general-meeting-of-shareholders-d8f6d597) — Source: Pharvaris
- 2026-05-29 10:50 EST — [Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026](https://biopharmsignal.com/news/PHVS/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026-f5146f6d) — Source: Pharvaris
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)